Document is current
Any future updates will be listed below
-
Authors
Patone, Martina
Mei, Xue W. https://orcid.org/0000-0002-6279-4884
Handunnetthi, Lahiru https://orcid.org/0000-0002-8242-3722
Dixon, Sharon
Zaccardi, Francesco
Shankar-Hari, Manu https://orcid.org/0000-0002-5338-2538
Watkinson, Peter https://orcid.org/0000-0003-1023-3927
Khunti, Kamlesh
Harnden, Anthony
Coupland, Carol A. C. https://orcid.org/0000-0002-2327-3306
Channon, Keith M.
Mills, Nicholas L. https://orcid.org/0000-0003-0533-7991
Sheikh, Aziz https://orcid.org/0000-0001-7022-3056
Hippisley-Cox, Julia https://orcid.org/0000-0002-2479-7283
- License Information
-
More Information
Article History
Received: 15 October 2021
Accepted: 15 November 2021
First Online: 14 December 2021
Competing interests
: A.S. is a member of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group, the Scottish Government’s Standing Committee on Pandemics and AstraZeneca’s Thrombotic Thrombocytopenic Advisory Group. All roles are unremunerated. J.H.-C. reports grants from NIHR Biomedical Research Centre, Oxford, John Fell Oxford University Press Research Fund and Cancer Research United Kingdom (CR-UK) grant no. C5255/A18085, through the CR-UK Oxford Centre, and grants from the Oxford Wellcome Institutional Strategic Support Fund (204826/Z/16/Z) and other research councils during the conduct of the study. J.H.-C. is an unpaid director of QResearch, a not-for-profit organization that is a partnership between the University of Oxford and EMIS Health who supplied the QResearch database used for this work. J.H.-C. is a founder and shareholder of ClinRisk Ltd and was its medical director until 31 May 2019. ClinRisk Ltd produces open and closed source software to implement clinical risk algorithms (outside this work) into clinical computer systems. J.H.-C. is chair of the NERVTAG risk stratification subgroup and a member of Scientific Advisory Group for Emergencies COVID-19 groups and the NHS group advising on prioritization of use of monoclonal antibodies in SARS-CoV-2 infection. A.H. is a member of the Joint Committee on Vaccination and Immunisation. K.K. is a member of the Governments Scientific Advisory Group for Emergencies. All other authors declare no competing interests related to this paper.
